PARIS--(BUSINESS WIRE)--Regulatory News:
Pixium Vision (Paris:PIX) (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announced today that it was awarded the 2015 “Janus Healthcare Award,” with Caiman Design now part of the Silamir Group, for the commercial version of IRIS®, its first Vision Restoration System (VRS).
Pixium Vision’s SRV is designed for patients with retinitis pigmentosa, a genetic disease that leads to the progressive degeneration of the retina’s photoreceptors. The integrated and ergonomic design of the VRS, comprising a pair of goggles including a mini-neuromorphic-camera and a pocket computer, was a real challenge for the Pixium Vision and Silamir teams.
For Khalid Ishaque, CEO of Pixium Vision, “This award illustrates our patient-centric approach when it comes to system design and development as we always strive to propose comfort, ergonomics and aesthetics. We are delighted to join the club of recognized companies that use design to enhance the integration of high tech objects in daily lives.”
Created in 1953, the prestigious Janus Award is the French Institute of Design’s label of excellence. It is sponsored by the French Ministries of Industry and Foreign Trade. Each year, a multidisciplinary jury evaluates the creative process used in project development, from conception to realisation. It rewards the best products in terms of design using five criteria: economics, aesthetics, ergonomics, ethics and emotion. The awards are presented in a variety of sectors, from industry and retailing, to health, services and life sciences, as well as in personal services and urban applications.
About Pixium Vision (www.pixium-vision.com, @PixiumVision)
Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. The Company harnesses the rapid advances in visual processing, microelectronics / nanoelectronics, optoelectronics, neurobiology and intelligent software algorithms. Pixium Vision’s VRS are associated with a surgical intervention as well as a rehabilitation period.
Clinical trials are currently underway with the VRS IRIS® in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. Pixium Vision plans to file IRIS’s CE mark dossier before the end of 2015 and expects to launch IRIS® during the first half of 2016.
Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.
The company is ISO 13485 certified.
Pixium Vision is listed on Euronext (Compartiment C) in Paris.
ISIN: FR0011950641; Mnemo: PIX
IRIS® is a trademark of Pixium-Vision SA
This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.
For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company’s Registration Document filed with the AMF under number R15-069 on September 23, 2015 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).